Abstract
A group of 10 patients with malignant lymphoproliferative diseases resistant to any standard therapeutical modalities were treated with a high dose of alpha- 2-recombinant interferon (alpha- 2-rIF). Alpha- 2-rIF was administered at a total dose of 120 × 10 6 IU in a continuous infusion during 48 h. Two cycles of alpha- 2-rIF immunotherapy were employed with an interval of 1 month in between each. Serum and urinary beta- 2-microglobulin (B 2M) were examined prior to alpha- 2-rIF application and on days 2, 4, 6 afterwards. Alpha- 2-rIF treatment induced an increase in serum B 2M as noted on day 2 followed by a decline to below the normal range. The initial increased value was significantly higher as compared to either the pretreatment value or the normal physiological range. The reduced B 2M serum level was protracted and lasted until the second cycle of treatment. Similar but not so great changes in B 2M serum values were noted during the second application of alpha- 2-rIF. The changes of B 2M level in the urine, although less convincing, mimic those observed in the serum. The present results confirmed the biological activity of alpha- 2-rIF in malignant lymphoproliferative diseases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
